OTCMKTS:TRUMY

Terumo Stock Forecast, Price & News

$36.31

-0.36 (-0.98 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$36.14

Now: $36.31▼

$36.89

50-Day Range

$35.19

MA: $37.46▼

$41.78

52-Week Range

$31.20

Now: $36.31▼

$44.76

Volume20,222 shs

Average Volume35,427 shs

Market Capitalization$27.58 billion

P/E Ratio35.25

Dividend Yield0.52%

Beta0.38

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Medical & hospital equipment

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:TRUMY

Previous SymbolNASDAQ:TRUMY

CUSIPN/A

CIKN/A

Webwww.terumo.co.jp

Phone(133) 374-8111

Employees26,438

Year Founded1964

Debt

Debt-to-Equity Ratio0.32

Current Ratio2.60

Quick Ratio1.75

Price-To-Earnings

Trailing P/E Ratio35.25

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.79 billion

Price / Sales4.77

Cash Flow$1.48 per share

Price / Cash Flow24.60

Book Value$9.14 per share

Price / Book3.97

Profitability

EPS (Most Recent Fiscal Year)$1.04

Net Income$783.93 million

Net Margins12.58%

Return on Equity10.24%

Return on Assets6.29%

Miscellaneous

Outstanding Shares759,521,000

Market Cap$27.58 billion

Next Earnings Date5/17/2021 (Estimated)

OptionableNot Optionable

Headlines

Terumo is building a Global Therapeutic Interventional Oncology team to offer more therapeutic solution to cancer patients
April 12, 2021 | finance.yahoo.com

Terumo Co. (OTCMKTS:TRUMY) Short Interest Update
March 28, 2021 | americanbankingnews.com

Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.
February 23, 2021 | finance.yahoo.com

Lower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA Approval
January 12, 2021 | finance.yahoo.com

IceCure Inks Expanded Distribution Agreement with Terumo Corporation for Thailand
January 5, 2021 | markets.businessinsider.com

Terumo Enters 100th Anniversary Year
January 5, 2021 | finance.yahoo.com

MicroVention, Inc. Files Trade Secret Lawsuit Against Balt USA, LLC
December 23, 2020 | finance.yahoo.com

Terumo extends strategic collaboration with IceCure Medical
October 5, 2020 | seekingalpha.com

India ECB, FCCB and RDB data for August 2020
October 5, 2020 | in.reuters.com

MicroVention-Terumo Announces New Leadership
September 22, 2020 | finance.yahoo.com

Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19
August 24, 2020 | finance.yahoo.com

Neurointerventional Devices Market To Witness the Highest Growth Globally in Coming Years 2020-2025
July 22, 2020 | www.marketwatch.com

Terumo completes acquisition of Quirem Medical, acquires 80.1% of shares
July 15, 2020 | seekingalpha.com

Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field
July 15, 2020 | finance.yahoo.com

UV light robot destroys coronavirus in 2 minutes
May 12, 2020 | finance.yahoo.com

FDA grants emergency authorization to two blood purification systems
April 10, 2020 | finance.yahoo.com

Coronavirus update: 1.62 million cases worldwide, 97,200 deaths, and U.S. fatalities are second only to Italy
April 10, 2020 | finance.yahoo.com

Terumo Corporation (TRUMY)
March 26, 2020 | finance.yahoo.com

Disposable Clothing Market 2020 Demand Analysis and Growth Outlook - Baxter International Inc.(nys:BAX), Terumo Corp.TRUMF, Halyard Health
February 11, 2020 | www.marketwatch.com

MicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain Aneurysms
January 9, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.75 out of 5 stars

Medical Sector

1225th out of 2,016 stocks

Medical & Hospital Equipment Industry

5th out of 7 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Terumo.

2.3 Community Rank

Outperform Votes
Terumo has received 76 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Terumo has received 86 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Terumo has received 53.09% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Terumo and other stocks. Vote “Outperform” if you believe TRUMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRUMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.8 Dividend Strength

Dividend Yield
Terumo has a dividend yield of 0.52%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Terumo does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Terumo is 18.27%. This payout ratio is at a healthy, sustainable level, below 75%.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Terumo insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.02% of the stock of Terumo is held by institutions.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Terumo is 35.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.23.
Price to Earnings Ratio vs. Sector
The P/E ratio of Terumo is 35.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 43.26.
Price to Book Value per Share Ratio
Terumo has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$36.31

-0.36 (-0.98 %)

(As of 04/12/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TRUMY News and Ratings via Email

Sign-up to receive the latest news and ratings for TRUMY and its competitors with MarketBeat's FREE daily newsletter.

Terumo (OTCMKTS:TRUMY) Frequently Asked Questions

Is Terumo a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Terumo in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Terumo stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRUMY, but not buy additional shares or sell existing shares.
View analyst ratings for Terumo or view top-rated stocks.

What stocks does MarketBeat like better than Terumo?

Wall Street analysts have given Terumo a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Terumo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Terumo?

Terumo saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 800 shares, a decrease of 55.6% from the February 28th total of 1,800 shares. Based on an average daily volume of 24,000 shares, the short-interest ratio is presently 0.0 days.
View Terumo's Short Interest.

When is Terumo's next earnings date?

Terumo is scheduled to release its next quarterly earnings announcement on Monday, May 17th 2021.
View our earnings forecast for Terumo.

How has Terumo's stock price been impacted by COVID-19?

Terumo's stock was trading at $32.71 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TRUMY stock has increased by 11.0% and is now trading at $36.31.
View which stocks have been most impacted by COVID-19.

Is Terumo a good dividend stock?

Terumo pays an annual dividend of $0.19 per share and currently has a dividend yield of 0.52%. The dividend payout ratio of Terumo is 18.27%. This payout ratio is at a healthy, sustainable level, below 75%.
View Terumo's dividend history.

Who are Terumo's key executives?

Terumo's management team includes the following people:

Shinjiro Sato, President, CEO & Representative Director
Naoki Muto, Chief Financial & Accounting Officer
Kazuhisa Senshu, Chief Clinical & Regulatory Affairs Officer
Hiroaki Kasukawa, Chief Technology Officer & Executive Officer
Shouji Hatano, Director, Head-Compliance & Legal Affairs

Who are some of Terumo's key competitors?

Some companies that are related to Terumo include Henry Schein (HSIC), Patterson Companies (PDCO), Owens & Minor (OMI), BrewBilt Manufacturing (BBRW), Fuse Medical (FZMD) and InternetArray (INAR).
View all of TRUMY's competitors.

What is Terumo's stock symbol?

Terumo trades on the OTCMKTS under the ticker symbol "TRUMY."

How do I buy shares of Terumo?

Shares of TRUMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Terumo's stock price today?

One share of TRUMY stock can currently be purchased for approximately $36.31.

How much money does Terumo make?

Terumo has a market capitalization of $27.58 billion and generates $5.79 billion in revenue each year. The company earns $783.93 million in net income (profit) each year or $1.04 on an earnings per share basis.

How many employees does Terumo have?

Terumo employs 26,438 workers across the globe.

When was Terumo founded?

Terumo was founded in 1964.

What is Terumo's official website?

The official website for Terumo is www.terumo.co.jp.

Where are Terumo's headquarters?

Terumo is headquartered at 2-44-1 Hatagaya Shibuya-ku, Tokyo M0, 151-0072.

How can I contact Terumo?

Terumo's mailing address is 2-44-1 Hatagaya Shibuya-ku, Tokyo M0, 151-0072. The company can be reached via phone at (133) 374-8111 or via email at [email protected]

This page was last updated on 4/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here